Guided Therapeutics (GTHP) Long-Term Deferred Tax (2016 - 2024)
Guided Therapeutics recorded quarterly Long-Term Deferred Tax of $17.6 million in Q4 2024, down 16.48% quarter-over-quarter from $21.0 million in Q4 2019.
Guided Therapeutics' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $17.6 million for Q4 2024.
- In Q4 2024, Long-Term Deferred Tax changed N/A year-over-year to $17.6 million; the TTM figure through Dec 2024 stood at $17.6 million (changed N/A YoY), while the FY2024 annual figure was $17.6 million, changed N/A from the prior year.
- Long-Term Deferred Tax came in at $17.6 million for Q4 2024 at Guided Therapeutics, down from $21.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $17.6 million in Q4 2024 to a low of $17.6 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Guided Therapeutics | - | - | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 17.57 Mn |
| Dec 31, 2019 | 21.03 Mn |
| Dec 31, 2018 | 21.47 Mn |
| Dec 31, 2017 | 23.46 Mn |
| Dec 31, 2016 | 29.45 Mn |